Drug Profile
PZ 01
Alternative Names: Anti-CD19 CAR-T cell therapy - Pinze Lifetechnologies; PZ01Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Pinze Lifetechnology
- Developer Navy General Hospital; Pinze Lifetechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for clinical-Phase-Unknown development in B-cell lymphoma(In adolescents, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 28 Aug 2020 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 20 Jul 2017 Clinical trials in Acute lymphoblastic leukaemia (In adolescents, In adults, Second-line therapy or greater) in China (IV) (ChiCTR-ONh-17012060)